LQDA
Price
$71.21
Change
-$6.72 (-8.62%)
Updated
Jul 13 closing price
Capitalization
6.33B
23 days until earnings call
Intraday BUY SELL Signals
UNCY
Price
$5.09
Change
-$0.12 (-2.30%)
Updated
Jul 13 closing price
Capitalization
139.43M
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LQDA vs UNCY

LQDA vs UNCY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LQDA vs. UNCY commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LQDA is a Buy and UNCY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (LQDA: $71.21 vs. UNCY: $5.09)
Brand notoriety: LQDA and UNCY are both not notable
LQDA represents the Pharmaceuticals: Generic, while UNCY is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: LQDA: 59% vs. UNCY: 48%
Market capitalization -- LQDA: $6.33B vs. UNCY: $139.43M
LQDA [@Pharmaceuticals: Generic] is valued at $6.33B. UNCY’s [@Biotechnology] market capitalization is $139.43M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LQDA’s FA Score shows that 2 FA rating(s) are green whileUNCY’s FA Score has 0 green FA rating(s).

  • LQDA’s FA Score: 2 green, 3 red.
  • UNCY’s FA Score: 0 green, 5 red.
According to our system of comparison, LQDA is a better buy in the long-term than UNCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LQDA’s TA Score shows that 3 TA indicator(s) are bullish while UNCY’s TA Score has 4 bullish TA indicator(s).

  • LQDA’s TA Score: 3 bullish, 5 bearish.
  • UNCY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both LQDA and UNCY are a bad buy in the short-term.

Price Growth

LQDA (@Pharmaceuticals: Generic) experienced а -10.10% price change this week, while UNCY (@Biotechnology) price change was -5.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

LQDA is expected to report earnings on Aug 06, 2026.

UNCY is expected to report earnings on Aug 17, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($6.33B) has a higher market cap than UNCY($139M). LQDA YTD gains are higher at: 106.466 vs. UNCY (-11.785). LQDA has higher annual earnings (EBITDA): 53.8M vs. UNCY (-39.24M). LQDA has more cash in the bank: 223M vs. UNCY (54.6M). UNCY has less debt than LQDA: UNCY (941K) vs LQDA (185M). LQDA has higher revenues than UNCY: LQDA (288M) vs UNCY (0).
LQDAUNCYLQDA / UNCY
Capitalization6.33B139M4,556%
EBITDA53.8M-39.24M-137%
Gain YTD106.466-11.785-903%
P/E Ratio418.94N/A-
Revenue288M0-
Total Cash223M54.6M408%
Total Debt185M941K19,660%
FUNDAMENTALS RATINGS
LQDA: Fundamental Ratings
LQDA
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
4
SMR RATING
1..100
35
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
25
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LQDAUNCY
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
87%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LQDA
Daily Signal:
Gain/Loss:
UNCY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSVYX27.10N/A
N/A
Victory RS Value Y
FICIX17.34N/A
N/A
Cantor Fitzgerald Large Cap Fcs Cl R6
VWYFX55.48N/A
N/A
Voya Small Cap Growth A
JVARX40.94N/A
N/A
JPMorgan Value Advantage R5
HLRRX9.90-0.01
-0.10%
LDR High Income Realty Institutional

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with UNCY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then UNCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-8.62%
UNCY - LQDA
34%
Loosely correlated
-2.30%
GOSS - LQDA
34%
Loosely correlated
-15.09%
VIR - LQDA
32%
Poorly correlated
-2.41%
KROS - LQDA
32%
Poorly correlated
-5.93%
MNKD - LQDA
32%
Poorly correlated
-1.22%
More

UNCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, UNCY has been loosely correlated with NVCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if UNCY jumps, then NVCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UNCY
1D Price
Change %
UNCY100%
-2.30%
NVCT - UNCY
50%
Loosely correlated
+0.49%
ICU - UNCY
46%
Loosely correlated
-3.23%
VTGN - UNCY
44%
Loosely correlated
-2.05%
INMB - UNCY
40%
Loosely correlated
-4.12%
LQDA - UNCY
34%
Loosely correlated
-8.62%
More